JNJ

192.03

-0.36%↓

ABT

128.05

+0.39%↑

MDT

93.8

-2.87%↓

VEEV

289.29

-0.13%↓

A

145.94

+0.56%↑

JNJ

192.03

-0.36%↓

ABT

128.05

+0.39%↑

MDT

93.8

-2.87%↓

VEEV

289.29

-0.13%↓

A

145.94

+0.56%↑

JNJ

192.03

-0.36%↓

ABT

128.05

+0.39%↑

MDT

93.8

-2.87%↓

VEEV

289.29

-0.13%↓

A

145.94

+0.56%↑

JNJ

192.03

-0.36%↓

ABT

128.05

+0.39%↑

MDT

93.8

-2.87%↓

VEEV

289.29

-0.13%↓

A

145.94

+0.56%↑

JNJ

192.03

-0.36%↓

ABT

128.05

+0.39%↑

MDT

93.8

-2.87%↓

VEEV

289.29

-0.13%↓

A

145.94

+0.56%↑

Search

Compugen Ltd

Atidarymo kaina

1.68 -4

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.6

Max

1.74

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-161K

-7.3M

Pardavimai

-1M

1.3M

Pelno marža

-584.089

Darbuotojai

74

EBITDA

1M

-7.4M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+382.95% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-11-12

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

49M

187M

Ankstesnė atidarymo kaina

5.68

Ankstesnė uždarymo kaina

1.68

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Compugen Ltd Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-22 22:47; UTC

Įsigijimai, susijungimai, perėmimai

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project -- Update

2025-10-22 22:13; UTC

Įsigijimai, susijungimai, perėmimai

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project

2025-10-22 21:20; UTC

Uždarbis

Correction to IBM 3Q Sales Jump Article

2025-10-22 20:57; UTC

Uždarbis

SAP Posts Higher 3Q Revenue, Operating Profit

2025-10-22 23:46; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-10-22 23:46; UTC

Rinkos pokalbiai

Nikkei May Decline Amid U.S.-China Trade Tensions -- Market Talk

2025-10-22 23:41; UTC

Rinkos pokalbiai

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

2025-10-22 23:38; UTC

Rinkos pokalbiai

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

2025-10-22 23:15; UTC

Uždarbis

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 4th Update

2025-10-22 22:28; UTC

Rinkos pokalbiai

Alcoa Cautions About Spending More on U.S. Smelters -- Market Talk

2025-10-22 22:02; UTC

Uždarbis

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 3rd Update

2025-10-22 21:59; UTC

Įsigijimai, susijungimai, perėmimai

Williams Cos.: Entered Into 1.5 Mtpa LNG Offtake Obligation >WMB

2025-10-22 21:58; UTC

Įsigijimai, susijungimai, perėmimai

Williams Cos. to Buy 10% Interest in Louisiana LNG LLC >WMB

2025-10-22 21:57; UTC

Įsigijimai, susijungimai, perėmimai

Williams Cos. to Buy 80% Ownership In, Become Operator of Driftwood Pipeline >WMB

2025-10-22 21:56; UTC

Įsigijimai, susijungimai, perėmimai

Williams Cos.: Strategic Partnership Entered With Woodside Energy to Invest in Louisiana LNG Project >WMB

2025-10-22 21:47; UTC

Įsigijimai, susijungimai, perėmimai

Woodside: Williams to Assume LNG Offtake Obligations for 10% of Produced Volumes

2025-10-22 21:47; UTC

Uždarbis

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

2025-10-22 21:47; UTC

Įsigijimai, susijungimai, perėmimai

Woodside: Williams to Contribute Its Share of Capex for LNG Facility, Pipeline

2025-10-22 21:46; UTC

Įsigijimai, susijungimai, perėmimai

Woodside Energy Says Williams Deals Worth US$378 Million Including Capital Reimbursement

2025-10-22 21:45; UTC

Įsigijimai, susijungimai, perėmimai

Woodside Energy to Sell 80% Interest in Driftwood Pipeline Co. to Williams

2025-10-22 21:45; UTC

Įsigijimai, susijungimai, perėmimai

Woodside Energy to Sell 10% Interest in Louisiana LNG Holding Co. to Williams

2025-10-22 21:28; UTC

Rinkos pokalbiai
Uždarbis

Correction to Alcoa Tariff Market Talk

2025-10-22 21:25; UTC

Uždarbis

Wall Street Wonders if Grail's Cancer Test Results Are a True Positive -- Barrons.com

2025-10-22 21:17; UTC

Uždarbis

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 2nd Update

2025-10-22 21:09; UTC

Rinkos pokalbiai
Uždarbis

Alcoa Says Delivery Fee Covering Tariff Costs -- Market Talk

2025-10-22 21:00; UTC

Rinkos pokalbiai

ESG Roundup: Market Talk

2025-10-22 20:59; UTC

Uždarbis

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

2025-10-22 20:51; UTC

Uždarbis

SAP Reports Mixed Earnings. The Stock is Down. -- Barrons.com

2025-10-22 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-10-22 20:44; UTC

Uždarbis

Kaiser Aluminum: For the Full Yr 2025, Now Expects Conversion Rev to Be Flat to Up 5% Yr-Over-Yr and Raises Adjusted EBITDA Outlook to Improve 20% to 25% Yr-Over-Yr >KALU

Akcijų palyginimas

Kainos pokytis

Compugen Ltd Prognozė

Kainos tikslas

By TipRanks

382.95% į viršų

12 mėnesių prognozė

Vidutinis 8.5 USD  382.95%

Aukščiausias 13 USD

Žemiausias 4 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Compugen Ltd kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

2 ratings

2

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

1.25 / 1.48Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Very Strong Bearish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
help-icon Live chat